Keyphrases
Phase I Study
100%
Chemotherapy
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Serious Adverse Events
100%
Proton Therapy
100%
Hypofractionation
100%
Carboplatin-paclitaxel
75%
Overall Survival
50%
Maximum Tolerated Dose
50%
Dose Level
50%
Time-to-event
50%
Proton Beam Radiation Therapy
50%
Confidence Interval
25%
High Dose
25%
Dose-limiting Toxicity
25%
Dose Escalation
25%
Single Institution
25%
2-cycles
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Squamous Cell
25%
Stage II-III
25%
Nineteen
25%
Am(III)
25%
Starting Dose
25%
Concurrent Chemotherapy
25%
Consolidation Chemotherapy
25%
Common Terminology Criteria for Adverse Events (CTCAE)
25%
Control Rate
25%
Living Patients
25%
Radiation Chemotherapy
25%
Locoregional Control
25%
Esophagitis
25%
Pneumonitis
25%
3-cycle
25%
Posterior Probability
25%
Phase I Trial
25%
Distant Control
25%
Non-serious
25%
Method Assessment
25%
Local-regional Control
25%
Medicine and Dentistry
Adverse Event
100%
Non Small Cell Lung Cancer
100%
Proton Therapy
100%
Carboplatin
60%
Paclitaxel
60%
Overall Survival
40%
Radiation Therapy
40%
Drug Megadose
20%
Squamous Cell
20%
Consolidation Chemotherapy
20%
Pneumonia
20%
Esophagitis
20%
Phase I Trials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Chemotherapy
100%
Non Small Cell Lung Cancer
100%
Paclitaxel
60%
Carboplatin
60%
Maximum Tolerated Dose
40%
Overall Survival
40%
Pneumonia
20%
Esophagitis
20%
Phase I Trials
20%